The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some positive developments at rival Novo Nordisk NVO were the primary reasons ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

That’s up from $517 million a year ago, during the drug’s first full quarter on the market. Lilly shares shed more than $90 in value, falling nearly 11% to $804.06 Thursday afternoon.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...

2 The cases are Eli Lilly and Co. v. Strive Pharmacy LLC d/b/a Strive Compounding Pharmacy, case no. 1:2025cv00401 in the U.S. District Court for the District of Delaware, and Eli Lilly and Co. v ...

This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.

Eli Lilly and Company CEO David Ricks stands as President Donald Trump speaks about investing in America in the Cross Hall of the White House, Wednesday, April 30, 2025, in Washington.

That’s up from $517 million a year ago, during the drug’s first full quarter on the market. Lilly shares shed more than $90 in value, falling nearly 11% to $804.06 Thursday afternoon. Broader ...

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival ...